By Small Pharma Analyst : A few months ago, Merck (NYSE: MRK ) surprised investors by acquiring Idenix (NASDAQ: IDIX ) for $3.85 billion, a 239% premium to its closing share price of the prior day. This was an unexpected acquisition
of small-cap biotech companies like Idenix (NASDAQ: IDIX ) and Intermune (NASDAQ: ITMN ) . Why so many pharma deals ..... world, has agreed to pay about $3.85 billion to acquire Idenix Pharmaceuticals . Idenix is the developer of an important drug for hepatitis
mostly to the performance of Idenix Pharmaceuticals Inc (NASDAQ: IDIX ) and Micron Technology (NASDAQ ..... Merck (NYSE: MRK ) acquired IDIX at $24.50 a share. Although ..... stake, Baupost sold out of IDIX August 12, 2014. Four days
By R.S. Analytics : Arrowhead Research Corp. (NASDAQ: ARWR ) is a biopharmaceutical company targeting RNAi therapeutics. There are multiple compounds in Arrowhead's pipeline but the highest priority compound, and the focus of this article, is ARC-520 for hepatitis B. ARC-520 is being studied as a
figures, Merck & Co. (NYSE: MRK ) decided to bolster its own hepatitis C franchise with the purchase of Idenix Pharmaceuticals (NASDAQ: IDIX ) earlier this year for $3.85 billion. While that figure pales in comparison to Gilead's purchase
By Balanced Investing : The players of the drug manufacturing industry constantly grapple with the reality of patent expiries. Merck (NYSE: MRK ), being one of the renowned companies in the industry, is continuously on the move to commercialize its new wave of innovative discoveries to maintain and
coincided with a timely piece at the time of concern surrounding patent litigation and Merck & Co.'s (NYSE: MRK ) buyout of Idenix (NASDAQ: IDIX ). Beyond intellectual property, Idenix has experimental hepatitis C products Complete Story »
By Don Dion : Due to the recent release of its blockbuster hepatitis-C drug, Sovaldi, that is estimated to have nearly $5 billion in sales in the first 6-months of 2014, Gilead Sciences Inc. (NASDAQ: GILD ) is fighting a legal battle to hold off competitors who are claiming patent infringement and
Idenix Pharmaceuticals (NASDAQ: IDIX ): Q2 EPS of -$0.43 misses by $0.22 . Press Release Post your comment!
June 9 (Reuters) - Merck & Co Inc said it would buy Idenix Pharmaceuticals Inc in a deal valued at about $3.85 billion to complement its hepatitis C portfolio.